Search

Your search keyword '"Cascini GL"' showing total 140 results

Search Constraints

Start Over You searched for: Author "Cascini GL" Remove constraint Author: "Cascini GL"
140 results on '"Cascini GL"'

Search Results

51. Elevated whole blood viscosity is associated with an impaired insulin-stimulated myocardial glucose metabolism.

52. Pediatric Huntington Disease Brains Have Distinct Morphologic and Metabolic Traits: the RAREST-JHD Study.

53. A Methodology to Measure Glucose Metabolism by Quantitative Analysis of PET Images.

54. Immune-related [ 18 F]FDG PET findings in patients undergoing checkpoint inhibitors treatment: correlation with clinical adverse events and prognostic implications.

55. Sex-specific differences in myocardial glucose metabolic rate in non-diabetic, pre-diabetic and type 2 diabetic subjects.

56. Computed tomography: Diagnostic detection of complete pericardial agenesis: A case report.

57. The Role of Imaging of Lymphatic System to Prevent Cancer Related Lymphedema.

58. A case of pleural lipoma evaluated with multi-imaging methods.

59. Primary large B-cell lymphoma involving the cerebellopontine angle mimic acoustic schwannoma: Role of MR Spectroscopy in differential diagnosis. A case report.

60. Role of Nuclear Sentinel Lymph Node Mapping Compared to New Alternative Imaging Methods.

61. Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update.

62. 18 F-PSMA-1007 salivary gland dosimetry: comparison between different methods for dose calculation and assessment of inter- and intra-patient variability.

63. Impaired insulin-stimulated myocardial glucose metabolic rate is associated with reduced estimated myocardial energetic efficiency in subjects with different degrees of glucose tolerance.

64. Effects of 26 weeks of treatment with empagliflozin versus glimepiride on the myocardial glucose metabolic rate in patients with type 2 diabetes: The randomized, open-label, crossover, active-comparator FIORE trial.

65. Cross-sectional evaluation of FGD-avid polyostotic fibrous dysplasia: MRI, CT and PET/MRI findings.

66. Functional connectivity of the cortico-subcortical sensorimotor loop is modulated by the severity of nigrostriatal dopaminergic denervation in Parkinson's Disease.

67. Metabolic Syndrome Is Associated With Impaired Insulin-Stimulated Myocardial Glucose Metabolic Rate in Individuals With Type 2 Diabetes: A Cardiac Dynamic 18 F-FDG-PET Study.

68. Unespected dectection of unruptured brain arteriovenous malformation with 18 F-DOPA PET/MR.

69. MAFLD progression contributes to altered thalamus metabolism and brain structure.

70. Tailored Molecular Imaging of Pheochromocytoma and Paraganglioma: Which Tracer and When.

73. 64CuCl2 PET/CT as a potential new imaging method in prostate cancer: illusion or reality?

74. FDG-CT/PET false positive case in hip prosthesis: a clue to avoid error.

75. Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET.

76. The Role of Molecular Imaging in a Muscle-Invasive Bladder Cancer Patient: A Narrative Review in the Era of Multimodality Treatment.

77. Advanced Imaging Techniques for Radiotherapy Planning of Gliomas.

79. Reduction in Global Myocardial Glucose Metabolism in Subjects With 1-Hour Postload Hyperglycemia and Impaired Glucose Tolerance.

80. Not all that glitters is COVID! Differential diagnosis of FDG-avid interstitial lung disease in low-prevalence regions.

81. PET/CT in thyroid cancer - the importance of BRAF mutations.

82. Impact of [ 64 Cu][Cu(ATSM)] PET/CT in the evaluation of hypoxia in a patient with Glioblastoma: a case report.

83. Track density imaging: A reliable method to assess white matter changes in Progressive Supranuclear Palsy with predominant parkinsonism.

84. The Molecular Effects of Ionizing Radiations on Brain Cells: Radiation Necrosis vs. Tumor Recurrence.

85. Value of Multimodal Imaging Approach to Diagnosis of Neurosarcoidosis.

86. Microstructural changes of normal-appearing white matter in Vascular Parkinsonism.

87. Neuroimaging and Neurolaw: Drawing the Future of Aging.

88. 68Ga/64Cu PSMA Bio-Distribution in Prostate Cancer Patients: Potential Pitfalls for Different Tracers.

89. Clinical, electrophysiological, and imaging study in essential tremor-Parkinson's disease syndrome.

90. Microvascular Invasion in HCC: The Molecular Imaging Perspective.

91. Comparison Between 64 Cu-PSMA-617 PET/CT and 18 F-Choline PET/CT Imaging in Early Diagnosis of Prostate Cancer Biochemical Recurrence.

92. An Innovative Framework for Bioimage Annotation and Studies.

93. Molecular imaging of brain tumors with radiolabeled choline PET.

94. Ictal 18F-FDG PET/MRI in a Patient With Cortical Heterotopia and Focal Epilepsy.

95. Structural connectivity differences in motor network between tremor-dominant and nontremor Parkinson's disease.

97. Diagnostic Accuracy of 64 Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience.

98. PET/CT with 18 F-choline: Physiological whole bio-distribution in male and female subjects and diagnostic pitfalls on 1000 prostate cancer patients: 18 F-choline PET/CT bio-distribution and pitfalls. A southern Italian experience.

99. The SGK1 Kinase Inhibitor SI113 Sensitizes Theranostic Effects of the 64CuCl2 in Human Glioblastoma Multiforme Cells.

100. CADA-computer-aided DaTSCAN analysis.

Catalog

Books, media, physical & digital resources